GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » 3-Year EPS without NRI Growth Rate

CBIO (Crescent Biopharma) 3-Year EPS without NRI Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2025. Start your Free Trial

What is Crescent Biopharma 3-Year EPS without NRI Growth Rate?

Crescent Biopharma's EPS without NRI for the six months ended in Dec. 2024 was $-0.92.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Competitive Comparison of Crescent Biopharma's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Crescent Biopharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescent Biopharma's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's 3-Year EPS without NRI Growth Rate falls into.


;
;

Crescent Biopharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Crescent Biopharma  (NAS:CBIO) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Crescent Biopharma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Crescent Biopharma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Crescent Biopharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.